Search International and National Patent Collections
|1. (WO2016052971) HERCEPTIN-PHOTOSENSITIZER CONJUGATE FOR BREAST CANCER DIAGNOSIS AND PRODUCTION METHOD THEREFOR|
|Applicants:||THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
|Title:||HERCEPTIN-PHOTOSENSITIZER CONJUGATE FOR BREAST CANCER DIAGNOSIS AND PRODUCTION METHOD THEREFOR|
The present invention relates to an antibody-photosensitizer conjugate for cancer (particularly breast cancer) diagnosis and a production method therefor and, specifically, to a herceptin-photosensitizer conjugate which shortens diagnosis time and has an enhanced tumor diagnosis ability, the conjugate being obtained by merging, through chemical bonding, a photosensitizer and an anti-HER2 antibody (herceptin) which is specific to HER2, in order to diagnose a tumor which expresses HER2. It is expected that a conjugate for cancer diagnosis or treatment, in which maleimide, polyethylene glycol and a photosensitizer are sequentially coupled to an anti-HER2 antibody, has the advantages of: compared to an existing hydrophobic photosensitizer, showing higher solubility and higher efficiency in reactive oxygen species production at the time of light irradiation due to introduction of water-soluble polyethylene glycol into a photosensitizer having a carboxyl group; requiring no surfactant due to compensation of existing problems caused when an anti-HER2 antibody (herceptin) is soley used, i.e., the problems that several processing steps must be carried out, and that it is essential to use a surfactant; and being capable of being applied as an immunochemical coloring material for process-shortened breast cancer diagnosis. In addition, a production method for a conjugate (anti-HER2 antibody-maleimide-polyethylene glycol-photosensitizer) of the present invention can simply and easily merge a photosensitizer with an anti-HER2 antibody through a graduated and sequential method and, particularly, merges maleimide with a first conjugate having polyethylene glycol-photosensitizer combined therein, thereby enabling stable anti-HER2 antibody (herceptin) merger.